Review of biologics in allergic contact dermatitis.
Jushya BhatiaAnkur SarinUwe WollinaTorello LottiAlexander A NavariniSimon M MuellerStephan GrabbeJoachim SalogaGhasem R RokniMohamad GoldustPublished in: Contact dermatitis (2020)
The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes its management challenging. With advances in the understanding of the cellular and molecular pathogenesis of ACD, newer therapeutic targets are becoming apparent. In particular, the use of biologics has gained momentum, given the specificity of their action. This article aims to review the presently available data on the use of biologics in ACD. English-language-based literature available on the use of biological therapy was thoroughly probed in the following databases as on October 14, 2019: PubMed, Google Scholar, The Cochrane library, Embase, Scopus, and EBSCO. The following keywords were used: "contact dermatitis", "allergens", "delayed-type hypersensitivity reaction", "biologics", "biological therapy", "monoclonal antibodies", "patch testing", "TNF-α inhibitors", "infliximab", "adalimumab", "etanercept", "dupilumab", "omalizumab", "secukinumab", "ustekinumab", "rituximab".
Keyphrases
- rheumatoid arthritis
- atopic dermatitis
- ankylosing spondylitis
- juvenile idiopathic arthritis
- systematic review
- big data
- ulcerative colitis
- early onset
- allergic rhinitis
- drug induced
- magnetic resonance imaging
- single molecule
- molecular dynamics simulations
- magnetic resonance
- deep learning
- smoking cessation
- cell therapy
- electron transfer